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406Steroid-Refractory Acute GVHD: Lack of Long-Term
Improved Survival Using New Generation
Anticytokine Treatment
Alienor Xhaard,1 Vanderson Rocha,1,2 Benjamin Bueno,1 Regis Peffault de Latour,1
Julien Lenglet,1 Anna Petropoulou,1 Paula Rodriguez-Otero,1 Patricia Ribaud,1
Raphael Porcher,3 Gerard Socie,1,4 Marie Robin1There is no consensus on the optimal treatment of steroid-refractory acute graft-versus-host disease
(SR-aGVHD) after allogeneic hematopoietic stem cell transplantation. In our center, the treatment policy
has changed over time with mycophenolate mofetil (MMF) being used from 1999 to 2003, and etanercept
or inolimomab after 2004. An observational study compared survival and infection rates in all consecutive
patients receiving 1 of these 3 treatments. Ninety-three patients were included. Themain end point was over-
all survival (OS). Median age was 37 years. Acute GVHD developed at a median of 15 days after transplanta-
tion. Second-line treatment was initiated a median of 12 days after aGVHD diagnosis. Therapies wereMMF in
56%, inolimomab in 22%, and etanercept in 23% of the patients. Overall, second-line treatment response rate
was 45% (complete response: 28%), MMF: 55%, inolimomab: 35%, and etanercept: 28%. With 74 months
median follow-up, the 2-year survival was 30% (95% confidence interval: 22-41). Risk factors significantly
associated with OS in multivariate analysis were disease status at transplantation; grade III-IV aGVHD at
second-line treatment institution; and liver involvement. None of the second-line therapy influenced this
poor outcome. Viral and fungal infections were not statistically different among the 3 treatment options;
however, bacterial infections were more frequent in patients treated with anticytokines. Over an 11-year
period, 3 treatment strategies, including 2 anticytokines, give similar results in patients with SR-aGVHD.
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Acute graft-versus-host disease (aGVHD) is a ma-
jor complication after allogeneic hematopoietic stem
cell transplantation (alloHSCT). Its frequency varies
between 30% and 80% of transplants, depending on
the type of transplantation.The occurrence of aGVHD
reportedly decreases relapse of hematologic malignant
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6/j.bbmt.2011.06.012aGVHD (SR-aGVHD) is associated with increased
mortality, and the long-term mortality rate remains
around 70% [1,2].
First-line treatment of aGVHD is steroids at a dose
varying from 1 to 2 mg/kg/day. Response to first-line
steroid therapy is obtained in 40% to 70% of the pa-
tients [3-5]. Consequently, aGVHD remains steroid
resistant or refractory in 30% to 60% of the patients.
Numerous second-line treatments have been reported,
such as steroid bolus, antithymoglobulin (ATG), my-
cophenolate mofetil (MMF), tacrolimus (FK), siroli-
mus, and others. More recently, targeted treatments
against molecules, particularly cytokines implicated
in lymphocyte activation, have been used, including
monoclonal antibodies targeting the anti-interleukin
2 receptor (anti-IL2-R) or anticytokines molecules,
such as antitumor necrosis factor (anti-TNF) [3,5-
15]. Encouraging results have been reported with
these agents, with response rates around 50%.
However, until now, no survival advantage has been
demonstrated with any second-line treatment, and no
consensus has been reported concerning the optimal
second-line therapy for SR-aGVHD. Systematic
Biol Blood Marrow Transplant 18:406-413, 2012 407Second-Line Therapy of Steroid-Resistant aGVHDreviews on SR-aGVHD [2] indeed almost invariably
conclude that 1-year survival still ranges from 30%
to 40%, that most of the series include few patients,
and that follow-up time is usually too short.
With this in mind, we here report data on nearly
100 patients with long-term follow-up. In our center,
the policy to treat SR-aGVHD has changed
over time. From 1999 to 2003, MMF was regularly
used, whereas, after 2004, inolimomab (anti-IL2-R) or
etanercept (anti-TNF) were used: inolimomab was
preferentially used in patients with primarily skin
involvement and etanercept in patients with primarily
gut or liver involvement. We conducted a retrospective
study to compare response rates and infection incidents
after these second-line therapies and looked for im-
proved overall survival (OS), if any, in patients with
a first episode of SR-aGVHD.MATERIALS AND METHODS
Data, Definition, and Procedures
Patients included in this study received an allo-
HSCT at Saint-Louis Hospital, Paris, France. Children
above 4 years of age and adults were included. All
consecutive patients who received these second-line
therapies for SR-aGVHD were included from 1999
to 2010. All patients continued to receive a calcineurine
inhibitor (CNI) in addition to second-line treatment.
Some patients treated by MMF received tacrolimus
(FK), others received cyclosporine A (CsA), Because
no difference in patients’ characteristics and survival
was noticeable with either CsA or FK (data not shown),
patients were grouped into a single treatment, that is,
CNI and MMF. Patients who received a GVHD pro-
phylaxis by MMF could not be included in the second-
line therapy group MMF. Ninety-three patients met
the inclusion criteria. Acute GVHD was defined ac-
cording to modified Glucksberg’s criteria [16,17]. All
patients were treated with corticosteroids (2 mg/kg/
day) as first-line treatment. SR-aGVHD was defined
as a progressive disease after 3 days of treatment, stable
disease at 7 days of treatment, or partial response at 14
days. After the beginning of the second-line treatment,
steroids were initially continued at the same dosage for
a minimal duration of 14 days and slowly tapered over
time; CNI were continued. Disease staging and grad-
ing were prospectively evaluated at regular intervals
(day13,17, and114). Etanercept was given subcuta-
neously at 25 mg per dose twice a week for 4 weeks and
then pursued at 25 mg once a week for another 4
weeks. Inolimomab was given intravenously at 0.3
mg/kg/day for 8 days, then at 0.4 mg/kg 3 times
a week during 3 weeks. In case of progression or no re-
sponse, a third-line immunosuppressive treatment was
begun. All patients received antipneumococcal, antivi-
ral, and anti-Pneumocystis prophylaxes. All patientswere monitored weekly by polymerase chain reaction
(PCR) for Epstein-Barr virus (EBV), cytomegalovirus
(CMV), adenovirus, and toxoplasmosis. Blood cultures
were performed daily during hospitalization, and se-
rum galactomannan dosage was performed twice a
week. Preemptive treatment strategies were used for
CMV and EBV reactivations. For bacterial infections,
only sepsis, pneumonia, and documented infections
were taken into account. For viral infections, respira-
tory viral infection, CMV, EBV, adenoviral infection,
disseminated herpes infection, HHV6 encephalitis,
and varicella/zona (VZV) were taken into account. All
data were collected from the PROMISE database and
the patients’ charts, which are prospectively filled. All
patients gave their consent for data collection before
transplantation.Statistics
The main endpoint was OS in each treatment
group. Secondary endpoints were response to treat-
ment, infection rates, relapse rates, and mean treatment
cost. Response to treatment was judged into 4 cate-
gories. Complete response (CR) was defined as the
disappearance of any GVHD signs from all organs
involved during at least 1 month. Stable disease (SD)
was considered when the grading of GVHD in all or-
gans was identical after treatment compared with time
of treatment initiation. Progressive disease (PD) corre-
sponded to worsening of GVHD grading in at least
1 organ. Other patients were considered to have partial
response (PR). Factors associated with CR were ana-
lyzed using logistic regressionmodels. Cumulative inci-
dence of CR and infections after second-line treatment
were estimated using the usual methodology [18]. For
CR, progression and death were considered as compet-
ing events, and patients receiving a third-line treatment
with no evidence of progression (ie, while in PR or SD)
were censored at the time of third-line treatment initi-
ation. When comparing survival according to CR, sur-
vival of patients achieving CR was counted from the
time of first evidence of CR, whereas survival of patients
who did not achieve CR was counted from the date of
initiation of second-line treatment. Survival of patients
who received a third-line treatment with no evidence of
progression was censored at that time. Viral, bacterial,
and fungal infections were analyzed separately, with
death being considered as a competing event. The asso-
ciation between second-line treatment and infection
was analyzed using Cox proportional cause-specific
hazards model [19]. To model recurrence of
infectious episodes, the Anderson-Gill approach was
used, together with a robust variance estimator acco-
unting for possible patient clustering effects [20].
Survival curves were estimated using the Kaplan-
Meier product-limit estimator. Survival curves were
compared using the log-rank test, and factors associated
408 Biol Blood Marrow Transplant 18:406-413, 2012A. Xhaard et al.with survival were analyzed using Cox proportional
hazards models. The proportional hazards assumption
was checked by examination of Schoenfeld residuals
and Grambsch and Therneau’s lack-of-fit test [20].
Univariate analyses were first performed, and then
a multivariable analysis was used to adjust the estima-
tion of association between each second-line treatment
and overall survival. In the latter analysis, all factors
with P values \.15 in the univariate analyses were
considered, and no variable elimination procedure was
performed, because the aimwas not to derive a prognos-
tic score but to control for confounding. The variable
selection for consideration in the model was used to
avoid too many variables per event, although we chose
not to conform to the empirical ‘‘rule of thumb’’ [21].
Moreover, despite the entry criterion, donor type was
preferred over stem cell source because both variables
were closely related and the former led to a better
multivariable model fit. In addition to the crude
Kaplan-Meier estimates for each type of second-line
treatment, Cox model-based adjusted for covariates
curves were also computed using Ederer’s ‘‘exact’’ esti-
mate [22]. Survival and cumulative incidence are pre-
sented as estimates and 95% confidence intervals (95%
CI). Association of factors with CR is expressed in terms
of odds ratio (OR) (95% CI) and association of factors
with infection and survival in terms of hazard ratios
(HR) (95% CI). All tests were 2-sided, and P values
#.05 were considered as indicating significant associa-
tion.Analyseswereperformedusing theRstatistical soft-
ware version 2.10.1 (R Development Core Team, R
Foundation for Statistical Computing, Vienna, Austria).RESULTS
Patients and Transplantation Characteristics
(Table 1)
Median age was 37 years (range: 5-64). Fifty-six pa-
tients (60%) were male; 47 (50%) patients were trans-
planted for acute leukemia, 10 (19%) for chronic
lymphoid disease, and 14 (15%) for aplastic anemia.
Forty-seven (50%) patients had a partial remission or
an uncontrolled disease at time of transplantation.
Sixty-one (65%)patients received amyeloablative condi-
tioning regimen. Donor was an identical sibling, a
matched unrelated (10 out of 10 HLA matches) or mis-
matched unrelated donor in 30 (32%), 35 (38%), and
28 (30%)patients.Thirty (32%)male recipients received
transplants from female donors. Stem cell sources were
peripheral blood (PBSC), bone marrow (BM), and cord
blood (CB) in41 (44%),39 (42%), and13 (14%)patients,
respectively. All the patients received CsA as GVHD
prophylaxis, with methotrexate (57%) or MMF (25%).
ATGwas given asGVHDprophylaxis during the condi-
tioning regimen in 27 patients (29%). Neutrophil
engraftment was obtained in 91 (98%) patients.Treatment of Steroid Refractory aGVHD
Acute GVHD occurred at a median of 15 days after
transplantation (range: 4-105). First-line treatment
with 2 mg/kg/day steroids was initiated at a median
of 0 days (range: 24-11) from GVHD diagnosis. Pa-
tients who received MMF in the GVHD prophylaxis
did not receive second-line treatment with MMF.
Second-line treatmentwasMMF in 52 (56%), inolimo-
mab in 20 (22%), and etanercept in 21 (23%) patients,
and was initiated in median 12 days (range: 1-218) after
GVHD diagnosis. Details concerning SR-aGVHD
and response to second-line treatment are given in
Table 2. At SR-aGVHD diagnosis, grade III-IV
GVHD was more frequent in patients treated by eta-
nercept (72%) compared with those treated with inoli-
momab (35%) or MMF (41%). Forty of 47 evaluable
patients developed chronic GVHD (cGVHD), which
was, in most cases, chronic extensive.
Response to Second-Line Treatment
Figure 1 displays the cumulative incidence of com-
plete response after second-line treatment, with progres-
sion and death considered as competing events. Overall
response to second-line treatment was 45% with 28%
CR and 17% PR. Overall response (CR 1 PR) was
55%, 35%, and 28% with MMF, inolimomab, and eta-
nercept, respectively. Overall response per organ was
76%, 42%, and 22% for skin, gut, and liver involvement,
respectively. Details concerning response rate are shown
in Table 2. In univariate analysis, advanced disease sta-
tus, use of PBSC or CB instead of BM as source of
stem cells, use of an unrelated donor, more recent treat-
ment period, liver involvement, and grade III-IV at on-
set of SR-aGVHD were predictors for noncomplete
response (Table 3).OS
Median follow-up from the date of initiation of
second-line treatment was 74 months (range: 3-103).
During follow-up, 66 patients died, almost all of
them during the 24 first months following second-
line treatment (62 patients). Overall, median survival
was 6 months after second-line treatment (95% CI:
4-10), with 30% of patients surviving at 24 months
(95% CI: 22-41) and 25% at 60 months (95% CI:
17-36) (Figure 2A). Patients who achieved a CR have
much better survival rates (Figure 2B). GVHD was
the main cause of death (68%).
Risk factors associated with OS in univariate anal-
ysis are shown in Table 3. When comparing survival
according to second-line treatment, no significant dif-
ference was found among the 3 groups. Better OS with
MMF (P5 .090) (Figure 2D) in univariate analysis was
not confirmed in multivariate analysis (Table 3). In
multivariate analysis, disease status at transplantation,
Table 1. Patients’ Baseline Characteristics
Characteristics All Patients MMF Inolimomab Etanercept P value
No. Patients (%) 93 (100) 52 (56) 20 (22) 21 (23)
Age at transplantation, median (range) yrs 37 (5 to 64) 30 (5 to 58) 42 (5 to 64) 46 (10 to 60) .005
Gender, no. (%) .74
Male 56 (60) 31 (60) 11 (55) 14 (67)
Female 37 (40) 21 (40) 9 (45) 7 (33)
Disease, no. (%) .50
AL/MDS 54 (58) 30 (58) 12 (60) 12 (57)
LD 20 (22) 10 (19) 3 (15) 7 (33)
Others 19 (20) 12 (23) 5 (25) 2 (10)
Status, no. (%) .002
CR 46 (49) 20 (38) 14 (70) 12 (57)
PR 5 (5) 1 (2) 0 (0) 4 (19)
Uncontrolled 42 (45) 31 (60) 6 (30) 5 (24)
Transplant
Stem cell source, no. (%) .0002
BM 39 (42) 32 (62) 4 (20) 3 (14)
PB 41 (44) 13 (25) 13 (65) 15 (71)
CB 13 (14) 7 (13) 3 (15) 3 (14)
Conditioning, no. (%) .032*
TBI 12 Gy/Cy or TBI 12 Gy/Mel ± Fluda 32 (34) 16 (31) 7 (35) 9 (43)
Bu/Cy ± Fluda 18 (19) 14 (27) 3 (15) 1 (5)
Bu/AraC/Mel 8 (9) 8 (15) 0 (0) 0 (0)
Other MAC 3 (3) 2 (4) 0 (0) 1 (5)
Fluda/TBI 2 Gy ± other 11 (12) 2 (4) 3 (15) 6 (29)
Fluda/Bu ± Cy 8 (9) 8 (15) 0 (0) 0 (0)
Fluda/Mel 7 (8) 0 (0) 5 (25) 2 (10)
TBI 2Gy 3 (3) 1 (2) 1 (5) 1 (5)
Other RIC 3 (3) 1 (2) 1 (5) 1 (5)
ATG, no. (%) .0009
No 66 (71) 29 (56) 19 (95) 18 (86)
Yes 27 (29) 23 (44) 1 (5) 3 (14)
GVHD prophylaxis, no. (%) <.0001
CsA/MTX 53 (57) 35 (67) 10 (50) 8 (38)
CsA/MMF 21 (23) 0 (0) 8 (40) 13 (62)
CsA/MMF/MP 2 (2) 0 (0) 2 (10) 0 (0)
CsA/MP 3 (3) 3 (6) 0 (0) 0 (0)
CsA 14 (15) 14 (27) 0 (0) 0 (0)
Donor
Donor type, no. (%) .087
Identical sibling 30 (32) 21 (40) 4 (20) 5 (24)
Matched unrelated 35 (38) 13 (25) 11 (55) 11 (52)
Mismatched unrelated 28 (30) 18 (35) 5 (25) 5 (24)
Donor/recipient gender .76
Male/male 26 (28) 12 (23) 7 (35) 7 (33)
Male/female 16 (17) 11 (21) 3 (15) 2 (10)
Female/male 30 (32) 19 (37) 3 (15) 7 (33)
Female/female 18 (19) 10 (19) 4 (20) 4 (19)
Missing data 3 (3) 0 (0) 3 (15) 1 (5)
Donor/recipient CMV status, no. (%) .98
Negative/negative 28 (30) 14 (27) 6 (30) 8 (38)
Negative/positive 28 (30) 16 (31) 6 (30) 6 (29)
Positive/negative 15 (16) 8 (16) 4 (20) 3 (14)
Positive/positive 21 (23) 13 (25) 4 (20) 4 (19)
No. indicates number, AL, acute leukemia; MDS, myelodysplastic syndrome; LD, lymphoproliferative disorders (ie, Hodgkin and non-Hodgkin lymphoma,
multiple myeloma, chronic lymphocytic leukemia); CR, complete response; PR, partial response; BM, bonemarrow; PB, peripherial blood stem cells; CB,
cord blood; TBI, total body irradiation; AraC, aracytine; Bu, busulfan; Cy, cyclophosphamide; Mel, melphalan; Fluda, fludarabine; CMV, cytomegalovirus;
CsA, cyclosporine; Gy, Grey; ATG, antithymoglobulin; MAC, myeloablative; RIC, reduced-intensity conditioning; MMF, mycophenolate mofetil; MP,
methylprednisolone; MTX, methotrexate.
P values correspond to Kruskall-Wallis or Fisher exact tests.
*RIC versus MAC.
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involvement were significantly associated with worse
survival (Table 3).
Infectious Complications
One hundred seventeen viral infectious episodes
occurred in 55 patients during the 24 months following
second-line treatment, corresponding to a 24-month
cumulative incidence of 60% (95% CI: 49-69), and anincidence rate of 13.0 infections per 100 patient-months
(95% CI: 10.8-15.6). Most first infectious episodes
occurred during the first 3 months after second-line
treatment initiation (Figure 3A). No notable difference
was observed among the 3 second-line treatment
groups in terms of risk of viral infection (P 5 .34).
Eighty-four CMV infections occurred in 36 patients,
with 3 episodes of CMV diseases (digestive, pneu-
monia, and retinitis, 1 each). Sixteen patients had
Table 2. Steroid Refractory Acute GVHD at Second-Line Therapy Initiation and Response Rate
All Patients Mycophenolate Inolimomab Etanercept
No. (%) 93 52 (56) 20 (22) 21 (23)
GVHD at second-line therapy onset
Grade (%)
I 9 (10) 9 (17) 0 (0) 0 (0)
II 41 (44) 22 (42) 13 (65) 6 (29)
III-IV 42 (47) 21 (41) 7 (35) 15 (72)
Skin grade, no. (%)
0 25 (27) 13 (25) 1 (5) 11 (52)
1 16 (17) 12 (23) 2 (10) 2 (10)
2 18 (19) 13 (25) 2 (10) 3 (14)
3-4 34 (36) 14 (27) 15 (75) 5 (24)
Gut grade, no. (%)
0 41 (44) 26 (50) 13 (65) 2 (10)
1 15 (16) 9 (17) 2 (10) 4 (19)
2 13 (14) 8 (15) 1 (5) 4 (19)
3-4 24 (26) 9 (21) 4 (20) 11 (53)
Liver grade, no. (%)
0 67 (72) 36 (69) 17 (85) 14 (67)
1 15 (16) 10 (19) 1 (5) 4 (19)
2 8 (9) 4 (8) 2 (10) 2 (10)
3-4 3 (3) 2 (4) 0 (0) 1 (5)
Response to treatment
Overall response* 42 (45) 29 (55) 7 (35) 6 (28)
Skin response/patients evaluable (%)† 42/68 (76) 31/39 (79) 7/19 (37) 4/10 (40)
Gut response/patients evaluable (%)† 25/60 (42) 15/28 (54) 4/11 (36) 6/21 (29)
Liver response/patients evaluable (%)† 7/32 (22) 6/19 (32) 1/5 (20) 0/8 (0)
No. indicates number; GVHD, graft-versus-host disease.
*All responses shown in this table include complete and partial response to treatment.
†Response per organ was assessed among patients with this organ involvement.
410 Biol Blood Marrow Transplant 18:406-413, 2012A. Xhaard et al.17 EBV reactivations. No case of posttransplantation
lymphoproliferative disorder was diagnosed. Twelve
patients had 19 episodes of adenovirus disease. Other
viral infections included Herpes Simplex Virus (HSV)
(n5 7), VZV (n5 2) and respiratory viruses orHHV6.
At 24 months, 70 bacterial infectious episodes had
occurred in 38 patients. The 24-month cumulative in-Figure 1. Cumulative incidence of complete remission and competing
events. Figure 1 displays the cumulative incidence of CR after second-
line treatment, with progression and death considered as competing
events. At each time are depicted the estimated probability of CR (lower
curve), the estimated probability of progression or death (from the top
to the gray curve) and the estimated probability of still being in PR/SD
(between both curves). CR indicates complete response; PR, partial re-
sponse; SD, stable disease; PD, progression of GVHD.cidence was 41% (95% CI: 31-51), and the incidence
rate was 7.8 infections per 100 patient-months (95%
CI: 6.1-9.8). The hazard of bacterial infection was
found to be different among the 3 second-line treat-
ment groups (P 5 .005) (Figure 3B). More precisely,
compared with patients having received MMF, pa-
tients treated with inolimomab had a hazard of bacte-
rial infection 2.84 times higher (95% CI: 1.43-5.67),
and patients treated with etanercept 3.26 times higher
(95%CI: 1.46-7.25). These differences persisted when
adjusting for GVHD grade 3-4 and liver involvement,
with adjusted hazard ratios being 3.21 (95% CI 1.56-
6.60) and 3.05 (95% CI 1.33-6.96) for inolimomab
and etanercept, respectively. Adjusting for GVHD
grade 3-4 as well as liver and gut involvement pro-
duced similar results, with adjusted hazard ratios
2.83 (95% CI: 1.35-5.92) and 4.25 (95% CI: 1.71-
10.55) for inolimomab and etanercept, respectively.
Similar results were also found when considering the
first infectious episode only. In terms of cumulative in-
cidence at 24 months, this translated to a probability of
27% (95% CI: 16-40) in patients treated with MMF,
62% (95%CI: 34-81) in patients treated with inolimo-
mab, and 57% (95%CI: 31-76) in patients treated with
etanercept. Twenty episodes of pneumonia and 29 of
bacteremia were documented. Most of the bacterial in-
fections were because of Gram negative bacteria (in-
cluding 11 episodes of Pseudomonas species infections)
or anaerobic species. TenEnterococcus species infections
were documented. Nine episodes of Clostridium difficile
stool excretion were documented.
Table 3. Response to Second-Line Treatment and Survival Analysis
Factors Predicting Complete Response
to Second-Line Treatment
Survival Analysis
Univariable Model Multivariable Model
OR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Age, per 10 years 0.92 (0.71-1.2) .54 1.18 (1.01-1.37) .032 1.10 (0.92-1.32) .29
Gender
Male 1 1 1
Female 0.45 (0.17-1.22) .12 1.62 (0.99-2.66) .055 1.71 (1.00-2.94) .05
Disease status at transplant
Complete remission 1 1 1
Noncomplete remission 0.25 (0.09-0.67) .006 3.13 (1.85-5.27) <.0001 2.95 (1.62-5.37) .0004
Stem cell source
Bone marrow 1 1
PBSC 0.31 (0.12-0.85) .023 1.85 (1.07-3.20) .028
Cord blood 0.11 (0.013-0.91) .041 1.44 (0.68-3.04) .34
Donor
Identical sibling 1 1 1
Unrelated 0.17 (0.06-0.44) .0003 1.46 (0.84-2.52) .18 1.55 (0.83-2.88) .17
Conditioning
Reduced-intensity 1 1
Myeloablative 2.83 (0.95-8.44) .061 0.84 (0.51-1.4) .5
Recipient CMV status
Negative 1 1 1
Positive 1.03 (0.42-2.57) .94 1.78 (1.07-2.97) .027 1.62 (0.92-2.84) .095
Year of transplantation
1999-2002 1 1
2003-2007 0.29 (0.09-0.91) .035 1.35 (0.72-2.54) .35
2008-2010 0.18 (0.06-0.6) .005 1.63 (0.88-3) .12
GVHD grade (SR onset)
I-II 1 1 1
III-IV 0.24 (0.09-0.68) .007 2.93 (1.77-4.86) <.0001 3.24 (1.83-5.73) <.0001
Organ involved
Skin 1.32 (0.46-3.79) .61 0.75 (0.43-1.29) .29
Gut 0.58 (0.23-1.44) .24 1.39 (0.84-2.29) .2
Liver 0.25 (0.07-0.92) .037 4.02 (2.39-6.74) <.0001 2.96 (1.66-5.29) .0003
Maximal steroid dose, per 1 mg/kg* 0.81 (0.49-1.33) .41 0.96 (0.75-1.22) .73
Delay of aGVHD, per 10 days† 0.89 (0.69-1.14) .35 1.03 (0.92-1.16) .6
Delay of second-line
treatment, per 10 days‡
1.04 (0.88-1.23) .67 1.02 (0.94-1.1) .65
Second-line treatment
Mycophenolate 1 1 1
Inolimomab 0.16 (0.034-0.78) .023 0.97 (0.51-1.84) .93 1.65 (0.79-3.42) .18
Etanercept 0.25 (0.06-0.94) .041 1.84 (1.02-3.32) .042 1.66 (0.83-3.33) .15
PBSC indicates peripheral blood stem cells; aGVHD, acute graft-versus host disease; CMV, cytomegalovirus; OR, odds ratio; CI, confidence interval.
*Maximal steroid dose (can be 2 mg/kg, 3 mg/kg, 4 mg/kg, 5 mg/kg).
†Delay from date of transplantation to aGVHD diagnosis, per 10 days.
‡Delay from aGVHD diagnosis to second-line treatment, per 10 days.
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19% (95% CI: 11%-27%), corresponding to 20 epi-
sodes of fungal infections in 18 patients (aspergillosis,
n 5 13, candidemia, n 5 3, zygomycosis, n 5 1, and
Pneumocystis jirovecii pneumonia, n 5 2). AlthoughFigure 2. OS (A) and OS according to complete response (B) or to second
according to complete response to second-line treatment (B), and the adjusted
point-wise 95% confidence intervals, and ticks denote censored observationsthe probability of fungal infection seemed about one-
half for patients receiving etanercept than for other
patients, the hazard of fungal infection was not sig-
nificantly different among the 3 groups (P 5 .91)
(Figure 3C).-line therapy with adjustment (C). Figure 2 displays the OS (A), the OS
survival (C) according to second-line treatment. Dashed lines represent
.
Figure 3. Probability of viral (A), bacterial (B), and fungal (C) infections according to second-line therapy. Figure 3 displays the probabilities of viral (A),
bacterial (B), and fungal (C) infections at 24 months after second-line treatment initiation, according to the second-line treatment received.
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Costs of treatment for MMF, inolimomab, and
etanercept were calculated for a 4-week time period,
based on the price of medications provided by the
pharmacy of our hospital. CNI were considered to
be given intravenously (i.v.) in all the patients. Consid-
ering a 4-week treatment with i.v. CNI, costs of treat-
ment were 25117 Euros for inolimomab, 1464 Euros
for etanercept, 2130 Euros for i.v. FK with i.v.
MMF, and 1319 Euros for i.v. CsA with IV MMF.
DISCUSSION
The aim of our study was to analyze 3 different
strategies to treat SR-aGVHD. From 1999 to 2010,
we used for patients refractory to steroids either
MMF, inolimomab, or (3) etanercept. OS was not sig-
nificantly different among the 3 groups. Nevertheless,
bacterial infections were more frequent when using
new-generation treatments (groups 2 and 3), suggest-
ing a higher toxicity of these drugs. Risk factors for
mortality in these patients wereGVHDgrade and liver
involvement at onset of SR-aGVHD, irrespective of
the second-line therapy used.
We acknowledge the results of our study should be
interpreted with caution, notably because of its retro-
spective setting. To limit bias because of the retrospec-
tive analysis, SR-aGVHD definition and endpoints
(mortality, infections, response to treatment) have
been checked by at least 2 physicians. Another limita-
tion of this study is the time period effect. Indeed,
MMF has been used during the first period until
2003, and inolimomab or etanercept have been used
after this period. Supportive care, particularly anti-
infectious therapy, has progressed during the study pe-
riod, and we would expect that NRM could be higher
in patients from the first period (MMF group). Sur-
prisingly, the infection rate was even lower in patients
treated byMMF. Concerning etanercept and inolimo-
mab, there was a clear difference in patients’ character-
istics because our policy was to preferentially treat
patients with skin involvement with inolimomab and
those with gut or liver involvement with etanercept.The 3 groups of treatment were only comparable after
adjustment for site involvement and GVHD grade.
The response rates to inolimomab and etanercept
in our population seem somewhat lower than data pub-
lished by others, but most of these series included few
patients, had short follow-up with response rates rang-
ing from 51% to 100% for diverse anti-IL2-R mole-
cules and from 46% to 67% for anti-TNF [3,5-11,
15,23]. The response rate for MMF is in accordance
with previously published data, around 25% to 50%
[24,25]. OS was not significantly different in patients
treated by MMF, but lower infection rate and higher
response rate after MMF were observed. If we
referred to the randomized phase II trial comparing
a combination of corticosteroids with either
etanercept, MMF, denileukin, or pentostatin, a better
response rate and improved survival as well as a lower
infection rate were also found with MMF compared
with other treatments [26].
Currently, the 1-year mortality rate in patients
with SR-aGVHD remains similar (70%-90%) for
several decades, reflecting transient response or toxic-
ity in high-risk patients with grade III-IV or liver in-
volvement [1,27,28]. Interestingly, OS exceeding
70% at 12months in SR-aGVHDpatients in CR after
second-line therapy was not lower than OS observed
in our patients without GVHD or with GVHD re-
sponding to primary therapy [1]. As expected and as
already reported, a grade III-IV GVHD and a liver
involvement were predictive for poor survival [1].
Disease status was also predictor for worst survival,
probably because these patients were heavily treated
before transplantation and less able to support
GVHD and its consequences. However, we are still
not able to better predict patients’ outcomes, other
than confirming that higher grade at SR onset and
liver involvement lead to poor outcome.
The cumulative incidence of viral, bacterial, and
fungal infections, which are the major complications
in patients with SR-GVHD, were carefully studied.
Bacterial infection probability was significantly higher
in patients treated by anticytokine therapies compared
with MMF, whereas viral and fungal infection rates
Biol Blood Marrow Transplant 18:406-413, 2012 413Second-Line Therapy of Steroid-Resistant aGVHDwere similar. Anti-TNF is known to increase infection
risk in patients with autoimmune disease [29] and in
patients with GVHD [30]. Increased risk of infections
after inolimomab is less reported but seems to be sim-
ilar to the risk after etanercept.
When we calculated the 1-month costs per patient
for the 3 second-line strategies, we observed that the
inolimomab cost was 17- to 19-fold higher than
etanercept and MMF. In another way, 1-month
MMF or etanercept is 4-fold cheaper than 1 course
of rabbit ATG (Thymoglobuline 10 mg/kg,
Genzyme, France).
Alternative strategies to treat SR-aGVHD are
thus urgently needed and prospective phase II-III
studies should be the absolute priority to improve
the grim prognosis of SR-aGVHD.Onemulticentric,
prospective, randomized study comparing inolimo-
mab to ATG is currently ongoing in France. Al-
though MMF decreases infectious risk compared
with inolimomab or etanercept in this study, today
a significant proportion of patients receive MMF for
GVHD prophylaxis after reduced-intensity condi-
tioning and are thus no longer candidates for MMF
treatment of SR-aGVHD.ACKNOWLEDGMENT
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